His scientific interests lie mostly in Bladder cancer, Cystectomy, Surgery, Cancer and Lymph node. His Bladder cancer study is concerned with the field of Internal medicine as a whole. Bernard H. Bochner combines subjects such as Neoadjuvant therapy, Radiation therapy, Retrospective cohort study and Comorbidity with his study of Cystectomy.
His Surgery research is multidisciplinary, relying on both Transitional cell carcinoma, Urinary system and Evidence synthesis. Bernard H. Bochner has researched Cancer in several fields, including Chemotherapy, Cisplatin, Somatic cell, Mutation and Cytotoxicity. The various areas that Bernard H. Bochner examines in his Lymph node study include Urinary bladder, Radiology and Dissection.
His primary areas of study are Bladder cancer, Cystectomy, Internal medicine, Surgery and Oncology. His research on Bladder cancer concerns the broader Cancer. His work carried out in the field of Cystectomy brings together such families of science as Urinary system, General surgery, Urinary bladder and Lymph node.
Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together. The concepts of his Oncology study are interwoven with issues in Muscle invasive, Cisplatin, Germline, Prostate cancer and Cohort. His research integrates issues of Transitional cell carcinoma and Carcinoma in situ in his study of Urology.
His primary areas of investigation include Cystectomy, Bladder cancer, Internal medicine, Oncology and In patient. His Cystectomy research integrates issues from Surgery, Lymph node, Radiology, General surgery and Urothelial carcinoma. His research investigates the connection between Lymph node and topics such as Dissection that intersect with issues in Lymph.
In his work, Locally advanced is strongly intertwined with Cancer research, which is a subfield of Urothelial carcinoma. His Bladder cancer research includes themes of Disease and Urology. As a member of one scientific family, he mostly works in the field of Oncology, focusing on Targeted therapy and, on occasion, Metastatic Urothelial Carcinoma.
His main research concerns Bladder cancer, Cystectomy, Internal medicine, Oncology and Urology. His Bladder cancer research incorporates elements of Family medicine, Chemotherapy and General surgery. The various areas that Bernard H. Bochner examines in his Cystectomy study include Proportional hazards model, Surgery, Retrospective cohort study, Lymph node and Radiology.
His Lymph node course of study focuses on Pathological and Dissection and Lymph. His Carcinoma in situ study in the realm of Internal medicine interacts with subjects such as Perception, Cognition and Repetitive questions. Bernard H. Bochner works mostly in the field of Oncology, limiting it down to topics relating to Cohort and, in certain cases, Clinical state, Mdm2, Germline, Upper tract and Ras pathway.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
John P. Stein;Gary Lieskovsky;Richard Cote;Susan Groshen.
Journal of Clinical Oncology (2001)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang.
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed.
Nature Medicine (2017)
Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
Ahmad Shabsigh;Ruslan Korets;Kinjal C. Vora;Christine M. Brooks.
European Urology (2009)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.
Harry W. Herr;Bernard H. Bochner;Guido Dalbagni;S. Machele Donat.
The Journal of Urology (2002)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer;Gopa Iyer;Aphrothiti J. Hanrahan;Matthew Ivan Milowsky;Matthew Ivan Milowsky;Hikmat Al-Ahmadie.
Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis
Bernard H. Bochner;Richard J. Cote;Noel Weidner;Susan Groshen.
Journal of the National Cancer Institute (1995)
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.
Bernard H. Bochner;Guido Dalbagni;Michael W. Kattan;Paul Fearn.
Journal of Clinical Oncology (2006)
The mechanism of action of BCG therapy for bladder cancer—a current perspective
Gil Redelman-Sidi;Michael S. Glickman;Bernard H. Bochner.
Nature Reviews Urology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: